Although APP mutations associated with inherited forms of Alzheimer's disease (AD) are relatively rare, detailed studies of these mutations may prove critical for gaining important insights into the mechanism(s) and etiology of AD. Here, we present a detailed biophysical characterization of the structural properties of protofibrils formed by the Arctic variant (E22G) of amyloid-b protein (Ab40 ARC ) as well as the effect of Ab40 WT on the distribution of the protofibrillar species formed by Ab40 ARC by characterizing biologically relevant mixtures of both proteins that may mimic the situation in the heterozygous patients. These studies revealed that the Arctic mutation accelerates both Ab oligomerization and fibrillogenesis in vitro. In addition, Ab40 ARC was observed to affect both the morphology and the size distribution of Ab protofibrils. Electron microscopy examination of the protofibrils formed by Ab40 ARC revealed several morphologies, including: (1) relatively compact spherical particles roughly 4 -5 nm in diameter; (2) annular pore-like protofibrils; (3) large spherical particles 18-25 nm in diameter; and (4) short filaments with chain-like morphology. Conversion of Ab40 ARC protofibrils to fibrils occurred more rapidly than protofibrils formed in mixed solutions of Ab40 WT /Ab40 ARC , suggesting that co-incubation of Ab40 ARC with Ab40 WT leads to kinetic stabilization of Ab40 ARC protofibrils. An increase in the ratio of Ab WT / Ab MUT(Arctic) , therefore, may result in the accumulation of potential neurotoxic protofibrils and acceleration of disease progression in familial Alzheimer's disease mutation carriers.
Introduction
Alzheimer's disease (AD) is a progressive neurodegenerative disease that is characterized by the presence of extracellular amyloid plaques and intraneuronal neurofibrillary tangles in the brain. 1 -3 Biochemical analysis of amyloid plaques revealed that a main constituent is fibrillar aggregates of a 39-42 amino acid residue peptide referred to as the amyloid-b protein (Ab). 4 Several lines of evidence point towards a central role for the process of Ab fibril formation in the etiology of AD. Transgenic animals overexpressing mutant forms of its precursor, the amyloid precursor protein (APP), develop amyloid plaques comprising fibrillar Ab. 5 Several pathogenic AD mutations have been shown to affect the processing of APP, resulting in increased levels of Ab, in particular the more amyloidogenic variant Ab42. 6 These data implicate the process of amyloid fibril formation as the cause of disease progression and neurodegeneration in AD.
The molecular mechanism(s) by which fibrillization may cause neurodegeneration in AD and the nature of the toxic species remains controversial. 7 In vitro studies have demonstrated clearly that Ab fibril formation occurs via a complex multi-step nucleated polymerization mechanism that involves discrete soluble oligomeric intermediates termed ADDLS 8 or protofibrils, which disappear upon fibril formation. 9 -12 Several lines of evidence suggest that Ab protofibrils are a pathogenic species. First, there is a lack of a clear correlation between the amount of fibrillar Ab deposits at autopsy and AD severity, 13 whereas a correlation exists between soluble Ab levels in the brain and early cognitive dysfunction. 14, 15 It is noteworthy that in these studies the location of Ab (intracellular versus extracellular), and its aggregation state (monomer, oligomers, or fibrils) have not been well characterized. Second, transgenic animals that overproduce APP exhibit neuronal and behavioral abnormalities before amyloid plaques can be detected. 16, 17 Third, non-fibrillar, oligomeric forms of Ab alter neuronal function and/or cause cell death. 8,18 -20 Fourth, in some models, inhibiting fibril formation does not attenuate Ab-associated toxicity towards cultured neurons. 21, 22 Fifth, an autosomal dominant mutation (APPE693G or Ab (E22G)) with a clinical phenotype similar to that of idiopathic AD was shown to decrease Ab production in vivo and promote protofibril formation in vitro. 23 Most APP mutations associated with early onset familial Alzheimer's disease (FAD) are thought to accelerate AD by modulating the proteolytic processing of APP, which can increase the total concentration of Ab in the plasma and cerebrospinal fluid and/or produce an increase in the ratio Ab42/Ab40. 24, 25 However, the Arctic APP mutation (E693G) is an exception; it causes a reduction in Ab40 and Ab42 levels in plasma. 23 A reduction in Ab42 was observed also in conditioned media from cells transfected with APP E693G . 23 With all the evidence mounting in support of the pathogenic protofibril hypothesis, 26 one possible explanation for the toxicity of the Arctic mutation is that it promotes the formation of toxic aggregates, possibly protofibrils. 23 This hypothesis is supported by the increased propensity of the Arctic variant to form protofibrils in vitro. Recently, we showed that Ab40 ARC seems to more rapidly form novel annular and pore-like protofibrillar structures ("amyloid pores"), that resemble those formed by bacterial pore-forming toxins. 27 Here, we present detailed biophysical characterizations of protofibrils formed by Ab40 WT and the Arctic variant (Ab40 ARC ), as well as the biologically relevant mixtures of the two proteins that may model the situation in the heterozygous patients.
Results
The Arctic mutation accelerates Ab40 fibrillogenesis in vitro Under the conditions described here, Ab40 ARC forms fibrils more rapidly than Ab40 WT . Three different established protocols were used to prepare Ab40 (the DMSO/water/Tris method, the NaOH method 18 and the NaCl/PO 4 method; 23 see Materials and Methods). Ab40 WT , and Ab40 ARC (100 mM) were incubated at room temperature without stirring, and fibril formation was monitored by the thioflavin T (ThT) binding assay. ThT Figure 1 . The Arctic mutation accelerates Ab40 fibrillogenesis. A comparison of amyloid fibril formation (ThT binding) of Ab40 WT (broken lines) and Ab40 ARC (continuous lines) revealed that the Arctic mutation accelerates Ab fibrillization. (a) Three different protocols (DMSO/water/Tris method, blue; NaOH method, red; and NaCl/PO 4 method, green) were employed to ensure that the aggregation was not dependent on the method of Ab monomer preparation. Ab40 WT and Ab40 ARC (100 mM) were incubated at room temperature without stirring, and fibril formation was monitored using the ThT binding assay. (b) A fourth method of preparation gave a similar result. In this experiment, Ab40 WT (shaded bars) and Ab40 ARC (filled bars) monomers were isolated by SEC from a GdnHCl-treated A40b stock solution. Ab WT and Ab ARC (20 mM) were incubated at 37 8C without stirring, and fibril formation was monitored using the ThT binding assay.
is an amyloid specific dye that exhibits an enhanced emission maximum at 482 nm (excited at 450 nm) upon binding to amyloid fibrils. Fibrillization studies were carried out at room temperature, because the Arctic variant aggregates very rapidly at 37 8C (one to three hours at 100 mM). Figure 1(a) shows that Ab40 ARC showed a gradual increase of the ThT signal during the first 24 hours of incubation, whereas Ab40 WT showed no change in the ThT signal even after 48 hours of incubation (RT) at pH 7.4. The three different protocols yielded similar kinetic profiles for Ab40 WT and Ab40 ARC fibrillogenesis, all consistent with an accelerated rate of fibrillization for Ab40 ARC relative to Ab40 WT . To further confirm this finding, we used a fourth preparation protocol; lyophilized Ab40 WT and Ab40 ARC were denatured in 6 M guanidine-HCl (pH 7.4) and loaded onto a Superdex 75 SEC column, producing a single peak corresponding to an unstructured Ab monomer (as determined by gel-filtration and circular dichroism, data not shown). Monomeric Ab40 ARC and Ab40 WT were collected and subjected to conditions that favor fibril formation (37 8C, pH 7.4) at , 20 mM. Under these conditions, Ab40 ARC fibrillized much faster than Ab40 WT (Figure 1(b) ).
The Arctic mutation promotes the formation of annular protofibrils
To probe the effect of the Arctic mutation on the structural properties of Ab, in particular Ab protofibrillar intermediates, we monitored the aggregation of Ab WT and Ab ARC by electron microscopy (EM) as a function of time. Ab40 WT and Ab40 ARC (100 mM) were incubated at room temperature and aliquots were removed at regular intervals and examined by EM. After eight hours, only Ab ARC showed the formation of predominantly spherical protofibrillar structures with an average diameter of 4.5(^0.5) nm (Figure 2(a) ). After 14 hours, spheres (Figure 2(b), I ), short chain-like protofibrils (Figure 2(b) , II) and annular protofibrils (Figure 2(b) , III) were observed for Ab40 ARC . The chain-like protofibrils appeared to be composed of , 5 nm spherical species (Figure 2(b) , inset). Consistent with earlier reports, the spheres represent the assembly subunit of the chain-like protofibrils. 12, 28, 29 The annular protofibrils have an outer diameter of 6-9 nm, and an inner diameter of 1.5 -2 nm. Large spherical species with an average diameter of 18 -24 nm were observed also for Ab40 ARC (Figure 2(b) , IV). The amount of spherical and annular protofibrils started to diminish after 19 hours with short filaments and fibrils (not shown in the selected images) emerging as the predominant species, Figure 2 (c). Although amyloid fibril formation by Ab40 ARC did occur during the first 19 hours of incubation, the EM images in Figure 2 were chosen to focus only on the changes in the structural properties of protofibrillar Ab40 ARC . Ab40 WT (100 mM) did not exhibit significant protofibril formation over the incubation period (at room temperature) of 14 -48 hours. However, after 19 hours some nonfibrillar Ab40 WT aggregates and some very rare annular protofibrils could be detected by EM (Figure 2(d) ). These observations suggest that the Ab40 WT can form annular pore-like protofibrils, but much more slowly and to a lesser extent than Ab40 ARC . Interestingly, after 19 hours the ThT signal for the Ab40 ARC solutions had reached a plateau (Figure 1(a) ), and the majority of the monomer was consumed (suggesting complete conversion of Ab40 ARC to fibrils). However, EM showed that a significant amount of Ab40 ARC protofibrils persisted along with amyloid fibrils. Complete conversion of the remaining short chain-like protofibrils to fibrils did occur with time (, 72 -96 hours). Although we have focused on Ab40 ARC , preliminary studies with Ab42 ARC showed annular protofibrils forming more rapidly than Ab40 ARC , and annular protofibrils being the predominant protofibrillar species after eight hours of incubation at room temperature ( Figure 3 ).
Co-incubation of the Arctic variant with Ab40 WT results in the kinetic stabilization of Ab40 ARC protofibrils AD patients carrying the Arctic mutation are heterozygotes and express both Ab WT and Ab ARC . However, the ratio of Ab WT to Ab ARC (Ab ¼ Ab40 þ Ab42) in Arctic carriers (equimolar in vivo production cannot be assumed) and how it changes with age have not been determined. To determine whether changes in Ab40 ARC /Ab40 WT ratio have an affect on Ab aggregation in vitro, we compared the oligomerization and fibrillization properties of each variant to mixed solutions. During a 70 hour incubation at room temperature, the Ab40 WT (100 mM) sample did not show any significant protofibril formation (not shown) but a small and To facilitate further characterization of the different protofibrillar species by high-resolution EM and scanning transmission EM (STEM) methods, we sought to partially purify these species by sizeexclusion chromatography (SEC) fractionation using the stable protofibrils formed in an equimolar mixture of Ab40 WT (100 mM) and Ab40 ARC (100 mM). After a 16 hour incubation at room temperature, the mixture was spun at 13,000g, filtered through a 0.2 mm pore size nylon spin filter (to remove large aggregates) and then separated on a Superose 6 gel-filtration column (4 8C). Ab40 protofibrils were observed to be stable under these conditions (4 8C, 20 -30 hours). The oligomeric Ab40 eluted as broad peak between the void-volume peak and the Ab40 monomer peak ( Figure 5 ), suggesting the presence of protofibrils of different sizes and morphologies. The protofibrils were divided into seven fractions, which were concentrated to 15-20 mM and characterized by EM. The EM images ( Figure 6 ) revealed that early fractions (F1 -F5, only F2, F4, and F5 are shown) contained predominately short filaments, 4-5 nm wide and 50-100 nm long. Among the filaments were also spherical and ring-shaped structures (, 6-9 nm in diameter). In contrast, very few filaments were evident in the late fraction (F7), which contained numerous, ring-shaped structures. In addition, the filaments in fractions F5 -F7 were shorter than those in the earlier fractions, suggesting that partial separation of filaments of different sizes was achieved by the Superose 6 column. Examination of fraction F7 revealed that it contained a significant amount of annular protofibrils in addition to the spheres and large spherical oligomeric species. We did observe some variation in protofibril stability between different preparations. In some cases, a shift in the size distribution of the protofibrils toward higher molecular mass protofibrillar species was observed during the 16 -24 hour procedure. Shortening both the incubation time for inducing protofibril formation and the fractionation time could minimize these changes. Partial separation of the protofibrillar species was possible; in particular, separation of the chain-like protofibrils from the spheres and annular species. Incubation (20 -48 hours) of each of the purified protofibril fractions at 37 8C resulted in their conversion into amyloid fibrils (see Figure 2 of the Supplementary Material), suggesting that they are intermediates on the pathway or are in equilibrium with on-pathway intermediates leading to Ab fibril formation.
Single-particle averaging reveals a collection of distinct protofibril species
Using a mixed equimolar solution of Ab ARC and Ab WT (100 mM each), we employed negative-stain EM and single-particle averaging to analyze fraction F7 ( Figure 6 ) obtained by gel-filtration (Superose 6) fractionation. A representative image of fraction F7 is shown in Figure 7 (a). A total of 5126 particles were selected from 25 images of fraction F7. Multi-variate statistical analysis was then used to divide the 5162 particles into 100 output classes. These 100 classes fell into four major groups; the structures are shown in Figure 7 (b). The first group consisted of annular structures (amyloid pores) having an average diameter of approximately 6-9 nm and a central stain-filled cavity that is 1.5-2 nm in diameter (Figure 7 (b) Figure 4 . Kinetic stabilization of Ab40 ARC protofibrils by Ab40 WT . Protofibril formation during fibrillogenesis was measured using the two Ab40 variants, Ab40 ARC and Ab40 WT (100 mM), and relevant Ab40 ARC /Ab40 WT mixtures. Red, 100 mM Ab40 ARC ; blue, 100 mM Ab40 ARC / 50 mM Ab40 WT ; green, 100 mM Ab40 ARC /100 mM Ab40 WT ; black, 200 mM Ab40 WT .
1 -3). These amyloid pores are similar to those formed by a-synuclein and reminiscent of those observed for bacterial pore-forming toxins. 27, 30, 31 The second group showed rectangular particles with a mean diameter of 5 nm and varying length of 12-22 nm (Figure 7 (b), 4-6). The third group showed spherical aggregates with a mean diameter of 5(^0.5) nm (Figure 7(b), 7) . The fourth group Figure 5 . Fractionation of the protofibril peak. Partial separation of Ab40 protofibrillar species by fractionation of the oligomeric peak on a Superose 6 GF column. Gel-filtration chromatogram illustrating how the Ab40 oligomeric peak, which was obtained by incubating Ab40 ARC and Ab40 WT at equimolar concentration (100 mM) for 16 hours at room temperature, was divided into seven fractions (F1 -F7). The inset shows the amount of protofibrils and monomers present after the 16 hour incubation (RT). showed large spherical aggregates, which ranged in diameter from 18 nm to 25 nm (Figure 7(b),  8 and 9 ). The first, third and fourth groups represent the majority of structures observed in F7.
Quantitative analysis of the molecular mass distribution of Ab protofibrils by SVAU To determine the effect of the Arctic mutation on the size distribution of Ab protofibrils, we performed sedimentation velocity experiments on purified (separated from monomer) protofibrils of Ab40 WT , Ab40 ARC , Ab42 WT , and Ab42 ARC . The results, summarized in Table. 1, demonstrate that the Arctic mutation changes the size distribution of Ab protofibrils in favor of higher molecular mass species, especially in the case of Ab42 ARC . In addition, protofibrils formed by Ab40 ARC and Ab42 ARC were observed to undergo rapid conversion towards higher-order protofibrils. For example, sedimentation velocity analytical ultracentrifugation (SVAU) analysis of the total Ab ARC protofibrils, which were obtained by incubating Ab ARC (200 mM) for 16 -18 hours at room temperature, revealed three populations with average sedimentation coefficients of 8 S, 15 S and 21 S (Figure 8(a) ). Further incubation (three to seven hours more) at room temperature resulted in a shift of the sedimentation coefficient distribution towards the 21 S protofibrillar species (Figure 8(b) ). In the case of Ab42 ARC conversion into higherorder protofibrils occurred in the analytical ultracentrifuge during sedimentation velocity experiments. This rapid conversion, and the dynamic equilibrium that exist between the different Ab ARC protofibrillar species and fibrils precluded accurate determination of their molecular mass by sedimentation equilibrium, because 24 -30 hours of incubation under centrifugal force are required to reach equilibrium.
Quantitative analysis of the molecular mass distribution of Ab protofibrils by STEM STEM can be used to determine the molecular mass of individual particles, independent of their shape or hydrodynamic properties. To estimate the stoichiometric composition of the various Ab protofibrillar structures (spheres, large spherical structures, annular, and short filaments), the mass distribution of fractions (F5, F6 and F7) rich in these species were analyzed by STEM. Figure 9 (a) and (b) shows electron micrographs of unstained/ freeze-dried particles obtained from fraction F5 and F7, respectively. A significant number of short filament-like protofibrils were observed in fraction Figure 7 . Single-particle averaging reveals a collection of distinct protofibril species. EM image and single-particle averaging of protofibrils reveal pore-like, short filaments and sphere-like morphologies. (a) EM of negatively stained protofibrils from fraction 7 of the Superose 6 GF purified oligomeric peak of an equimolar mixed solution of Ab ARC and Ab WT (100 mM), which was incubated for 24 hours at room temperature prior to separation. (b) A gallery of class averages calculated from a total of 5162 particles. The size of each box corresponds to 50 nm. F5, whereas spherical protofibrils dominated fraction F7, consistent with the TEM data ( Figure 6 ). Protofibrils of various sizes could be distinguished and selected automatically by using a set of models of overlapping sizes in the PCMass program, which located all isolated particles in each image. The predominant particle shapes observed were: (a) short filaments (F1 -F6); (b) relatively amorphous round particles 13 -25 nm in diameter (F5 -F7); and (c) relatively compact particles roughly 5-8 nm in diameter (F7), occasionally with a central low-density area. Unlike SVAU, where it is difficult to directly assign a specific S value to a particular morphology, in STEM analysis an appropriate model based on the shape of the particles can be chosen to select the particles of each morphology, thus allowing us to estimate the mass distribution of each protofibrillar morphology. In this way, we grouped and analyzed the mass distribution of the short filaments ( Figure 9 (c)) and spherical species (Figure 9(d) ) (spheres of various sizes were grouped together) in the last three fractions (F5, F6 and F7). Global analysis of the short filament-like protofibrils in fractions F5, F6 and F7 (Figure 9 (c)) revealed a Gaussian molecular mass distribution with a broad peak of particles ranging in mass from 350 kDa to 800 kDa (81 -186 Ab monomers), with a trailing shoulder at 800-1000 kDa. Analysis of the spherical protofibrils, including annular and large globular structures gave a size from 80 -400 kDa, corresponding to 18-93 monomers ( Figure 9(d) ). The majority of the particles exhibited mass ranging from 150 kDa to 250 kDa (, 32 -59 monomers). In addition, STEM analysis revealed two other populations with mass distributions ranging from 295 kDa to 450 kDa and 680 kDa to 880 kDa (Figure 8(d) ), with the latter species corresponding to the largest spherical aggregates (18 -24 nm) observed by EM.
Discussion
The Arctic mutation promotes Ab oligomerization and fibrillogenesis
Although APP mutations associated with inherited forms of AD are relatively rare, detailed studies of these mutations may prove critical for gaining important insights into the mechanism and etiology of AD. 32 Several mutations (Flemish (A21G), Italian (E22K), Arctic (E22G), Dutch (E22Q) and Iowa (D23N)) that are located around the central hydrophobic core of Ab accelerate Ab oligomerization (E22Q, 10 and E22G 23 ) and fibrillogenesis (E22Q and D23N 33 ). Interestingly, the Flemish mutation was reported to decrease the rate of Ab fibrillogenesis. 34 The exact mechanism by which these mutations contribute to the pathogenesis of AD is unknown.
While the effect of Ab mutations on the structure and morphology of Ab fibrils has been investigated extensively, little is known about the effect of these mutations on the quaternary structure and morphology distribution of early prefibrillar intermediates, the protofibrils. Our studies on the fibrillogenesis of the Arctic variant demonstrate that the Arctic mutation promotes Ab oligomerization, consistent with data reported by Nilsberth and co-workers. 23 In addition, our data demonstrate that the Arctic mutation accelerates the Figure 8 . SVAU demonstrates rapid conversion between the different Ab40 ARC protofibrils. The distributions of sedimentation coefficients obtained from experiments performed on purified Ab40 ARC protofibrils. The sedimentation profiles were analyzed using the time-derivative method to yield the apparent distribution of sedimentation coefficients, g(s p ). The prominent maximum corresponds to the sedimentation coefficient of the major species in solution. The black line reflects the best least-squares fit of the data (O) to a three (a) and two species model using a Gaussian function.
fibrillogenesis of Ab40. This latter conclusion is in disagreement with data reported by Nilsberth and co-workers, 23 which suggest that this mutation does not affect the rate of Ab40 fibrillogenesis. The reasons for this disagreement may involve details of experimental conditions. In our studies, the kinetics of Ab fibril formation was monitored by measuring directly the binding of the amyloidspecific dye ThT to the Ab fibrils, whereas Nilsberth et al. used a technique (SEC) that measures the amount of fibril formation indirectly. Interpretation of the results from the latter approach is likely to be complicated by fibrils dissociation and/or interaction with the column matrix during the SEC experiments. Although the mechanism by which this mutation leads to an acceleration of Ab oligomerization and fibrillogenesis remains undefined, reduction of the charge state has been proposed to lead to an enhanced rate of oligomerization and/or amyloid fibril formation by amyloid-forming proteins.
35,36
The different Ab protofibrillar morphologies seem to be related Although previous studies have employed SVAU to estimate the molecular size distribution of protofibrils, the heterogeneity of the protofibril preparations used precluded the assignment of molecular mass averages to a particular protofibril species. To address this problem, we characterized our protofibril preparations using STEM, which allows quantitative mass analysis on specific protofibrillar morphologies and sizes. Time-dependent EM studies indicate that the spherical protofibrils (an average diameter of 4.5(^0.5) nm) represent the smallest Ab protofibrils detectable by EM and STEM. Mass measurements by STEM of the Figure 9 . STEM analysis reveals heterogeneous but discrete populations of Ab40 protofibrils. Quantitative STEM analysis of Ab40 particles obtained from purified oligomeric fractions of a 1:1 molar ratio solution of Ab40 ARC and Ab40 WT (100 mM). EMs of the unstained/freeze-dried particles of (a) fraction 5 (major species ¼ short filaments) and (b) fraction 7 (major species ¼ spherical and annular structures) and recorded by STEM. Light regions represent areas of high-mass density and dark regions represent areas of low mass density. Tobacco mosaic virus (TMV) was included in each specimen as an internal standard. Histograms showing molecular mass measurements of the particles from oligomeric fraction F5, F6 and F7 using two different models for (c) rectangular and (d) spherical species.
Mixtures of Wild-type and "Arctic" Ab40 Accumulate Protofibrils in vitro fraction containing mainly spheres and annular protofibrils (F7), revealed at least three major populations (based on their size) of protofibrils with average masses of 160 kDa, 300 kDa and 800 kDa. The smallest Ab oligomers (4.5 nm spheres) had an average mass of , 80 -100 kDa (19 -23 monomers) . These results are consistent with earlier reports suggesting that assembly intermediates must contain a minimum of ca 23 Ab40 monomers. 37 Although fraction F7 contained significant amount of annular protofibrils, it was very difficult to distinguish annular structures from spheres in the unstained STEM images. Based on EM and STEM, we propose that the second protofibrillar population with a mass distribution ranging from 150 kDa to 250 kDa (, 32 -59 monomers) corresponds to the amyloid pores. The highest mass species (800 kDa) may correspond to the large spherical (18 -25 nm) particles observed by EM. The short filaments with chain-like morphology exhibited a wide mass distribution (380 -800 kDa), consistent with the observed variability in their length. Given that the 4-5 nm spheres have an average mass of 80 -100 kDa, one could conclude that the smallest filament, which has an average mass of 400 kDa, is composed of , 4 -5 spherical protofibrillar intermediates. This estimate is consistent with our EM data (Figure 2 ). The 4 -5 nm spherical protofibrils resemble the spherical protofibrils first identified by AFM 9 -12 and neurotoxic oligomers referred to as ADDLs. 8 These spheres appear to be the precursors for the short filaments described above (see Figure 2(b) , II). 9, 12 Additional studies have reported operationally soluble aggregates of Ab protofibrils with diameters ranging from 8 nm to 18 nm and molecular masses of 0.5 MDa and 1 MDa (based on atomic force microscopy and SVAU measurements). 29, 38 During our studies of Ab and a-synuclein (both form spherical and annular protofibrils), 27 we have observed that spherical oligomers of both Ab and a-synuclein seem to have the highest affinity for the mica surface, whereas annular protofibrils have the lowest affinity; very few could be detected using enriched annular fractions (our unpublished results). In contrast, most Ab protofibrillar species appear to adsorb equally to carboncoated grids used for EM and STEM studies. These findings underscore the importance of supplementing imaging data (AFM or EM) with data from complementary techniques (SVAU and STEM).
Kinetic stabilization of Ab40 ARC protofibrils by Ab40 WT Individuals with the Arctic form of early onset familial AD are heterozygotes; presumably producing both Ab40 WT and Ab40 ARC in their brains. 23 The ratio of the different Ab peptides is likely to play a key role in governing the rate of Ab oligomerization and/or fibrillization, and, possibly, disease progression. Therefore, we compared fibrillogenesis of a mixture of Ab40 WT and Ab40 ARC to the individual variants Ab40 WT and Ab40 ARC (model of a homozygote, none of which is known to exist). Under conditions where Ab40 WT does not produce oligomers or fibrils, Ab40 ARC forms both protofibrils and fibrils. The Ab40 ARC protofibrils formed in the absence of Ab40 WT converted to fibrils, but addition of Ab40 WT to Ab40 ARC resulted in the stabilization and accumulation of protofibrils with eventual conversion to fibrils. The requirement for the relatively high stoichiometry of Ab40 WT (1:1) (addition of 25 mM Ab40 WT to 100 mM Ab40 ARC failed to stabilize protofibrils, data not shown) argues against a simple model where Ab40 WT monomers retard and/or inhibit Ab40 ARC assembly into amyloid fibrils by capping the ends of Ab40 ARC protofibrils. These results suggest that Ab40 WT and Ab40 ARC may interact at an early stage in the aggregation process. Interaction between monomeric Ab40 WT and monomeric and/or protofibrillar Ab40 ARC could interfere with the conformational changes required for protofibril elongation or interfere with protofibril assembly into amyloid fibrils leading to stabilization of Ab40 ARC protofibrils, as has been proposed to explain the inhibitory properties exhibited by Ab40 against Ab42 fibril formation. 39 Alternatively, protofibrils formed by Ab40 WT could interact with Ab40 ARC protofibrils in a way that interferes with further Ab40 ARC protofibrils self-assembly into amyloid fibrils. A similar observation has been made for a-synuclein, which is associated with familial Parkinson's disease. Human a-synuclein inhibits amyloid fibril formation of the more amyloidogenic mouse a-synuclein. 40 Further studies are required to distinguish between the models proposed above.
Annular, pore-like protofibrils may be responsible for Ab permeabilizing or channellike activity, and possibly AD While early oligomeric intermediates, protofibrils, have been implicated as the toxic species in several amyloid diseases including PD, 28,30,41 -43 HD, 44 British familial dementia, 45 systemic amyloidosis and familial amyloid polyneuropathy, 46 -48,8 -10 the mechanism of protofibril toxicity is not understood. Recently, we reported that pathogenic mutations in Parkinson's (A53T and A30P) and Alzheimer's disease (Arctic mutation, E22G) promote the formation of a distinct protofibrillar subtype that we refer to as amyloid pores. 27, 30 The morphology and the sizeselective permeabilization of synthetic vesicles by protofibril fractions containing the annular protofibrils, suggest a pore-like pathogenic mechanism that is reminiscent of bacterial toxins such as a-hemolysin. 49 Furthermore, several amyloidforming proteins that are associated with neurodegenerative diseases (Alzheimer's disease, Huntington disease and prion disease) have been demonstrated to form ion-permeable pores in vitro, at concentrations that are toxic in cell cultures. In addition, the tendency of amyloid proteins (including Ab, 27, 50 islet amyloid peptide amylin, 51, 52 polyglutamine repeats, 53 serum amyloid A, 54 b2-microglobulin, 55 prion proteins 56, 57 and a-synuclein 30, 58, 59 ) to form ion-permeable pores correlates with the presence of the pore-like structures. Thus, membrane disruption via pore formation may be a general mechanism of cytotoxicity for neurodegenerative diseases. 7,60 -62 In summary, our results suggest that an increase in the ratio of Ab WT /Ab ARC in FAD mutation carriers would favor the formation and accumulation of stable protofibrillar intermediates of Ab, resulting in an enhancement of its neurotoxic properties and accelerated disease progression. Although the nature of the pathogenic species in vivo and its mechanism of action remain controversial, our studies suggest that amyloid pore formation and membrane disruption may be linked to the pathogenesis of AD. If this hypothesis is correct, then drug-like molecules that inhibit pore formation and/or membrane permeabilization could be novel therapeutics against AD. Furthermore, the identification of small molecules or mutations that promote or inhibit amyloid pores should facilitate mechanistic studies.
Materials and Methods

Peptides
Ab40 WT and the Arctic variant Ab40 ARC (E22G), were purchased as TFA salts from the Biopolymer Facility at Brigham and Women's Hospital. All peptides were dissolved using their true peptide weight.
Solubilization of Ab
The WT and Arctic (Arc) peptides were dissolved individually using three different protocols to compare their fibrillogenesis in different buffers: (1) in the DMSO/water/Tris method peptides were dissolved in 100% DMSO then in water and Tris (pH 7.4). The final concentrations of peptide, DMSO, and Tris were 100 mM, 5%, and 10 mM, respectively. (2) The NaOH method, 18 peptides were dissolved using the NaOH method because of its ability to readily dissolve the peptide, control the pH, and reduce the rate of aggregation (see data below). Peptide was dissolved at 4.2 mg/ml in 1 mM NaOH containing phenol red, followed by empirically adding 130-150 ml of 10 mM NaOH to bring the sample to pH 7.0-7.4 using the added phenol red as an indicator. The sample was diluted with water and 10 £ PBS, bringing the final peptide concentration to 500 mM in PBS (pH 7.4). Samples were then diluted to 100 mM in water. (3) The NaCl/PO 4 method; 23 peptides were dissolved in water to 100 mM, with sodium phosphate and NaCl at final concentrations of 50 mM and 100 mM respectively.
Ab40 WT 1 Ab40 ARC mixed incubations
Individual peptides were dissolved with NaOH and PBS, as stated above, to give a concentration of 500 mM peptide in PBS (pH 7.4). WT and Arc were combined and diluted in water, giving a final concentration of 100 mM for each peptide.
Preparation and purification of Ab protofibrils
To prepare Ab protofibrils, lyophilized synthetic Ab (WT, Arc, or equimolar mixture of WT and Arc) was dissolved using one of the methods outlined above to obtain a total concentration of 100 mM. The peptide solutions were incubated at room temperature for 16-24 hours, before being centrifuged at 13,000g for five minutes to remove any insoluble particle(s). The supernatants were loaded onto either a Superdex 75 HR (Amersham Pharmacia) GF column (used to separate protofibrils from low molecular mass Ab species) equilibrated with protein buffer (5 mM Tris -HCl (pH 7.4), 70 mM NaCl) or a Superose 6 HR column (used to fractionate Ab protofibrils) equilibrated with protein buffer (10 mM Tris -HCl (pH 7.4), 150 mM NaCl). The protein was eluted at a flow-rate of 0.5 ml/minute and 0.5 ml fractions were collected. Fractions corresponding to the oligomeric peak were split into seven fractions (F1 -F7) and used for biophysical studies. Purified protofibril fractions were stored at 4 8C. Samples for EM and SVAU were prepared and used within one to ten hours unless indicated otherwise.
Quantification of monomeric and oligomeric Ab by gel-filtration
Samples of Ab (100 mM), WT, Arc or mixtures of WT and Arc were incubated at room temperature. Aliquots (50 ml) were removed from each sample at various times and filtered through a 0.2 mm pore size nylon spin filter (Costar) to remove any insoluble particle. The filtrate was injected onto a Superdex 200 HR column (10 mm £ 30 mm) equilibrated with protein buffer (10 mM Tris -HCl (pH 7.4), 150 mM NaCl). The relative amount of protofibrils and LMW Ab were quantified by calculating the area under the peak corresponding to each species using the Millenium Software (Waters, Milford, MA).
Thioflavin T assay for fibril formation
Fluorescence measurements of 5 ml of 100 mM Ab solution in 10 ml of 100 mM ThT þ 85 ml of 90 mM glycine-NaOH (pH 8.5 at 25 8C) (E x ¼ 450 nm, E m ¼ 482 nm) as described. 41 Electron microscopy and image processing Purified protofibrillar fractions of Ab were diluted twofold with protein buffer (10 mM Tris -HCl (pH 7.4), 150 mM NaCl) prior to adsorption to glow-discharged, carbon-coated copper grids. Grids were washed with four drops of buffer and stained with two drops of freshly prepared 0.75% (w/v) uranyl formate (Pfaltz & Bauer, Waterbury, CT 06708). Specimens were inspected with a Philips Tecnai 12 electron microscope operated at 120 kV and images were taken at a nominal magnification of 52,000 £ using low-dose procedures. For image processing, 25 images of Ab were digitized with a Zeiss SCAI scanner using a pixel size of 4.04 Å at the specimen level. From the digitized images, 5162 particles were selected for further computational processing using the SPIDER image processing package. 63 The 5162 particle images were subjected to ten rounds of alignment and classification specifying 100 output classes.
Sedimentation velocity analytical ultracentrifugation (SVAU)
Sedimentation velocity data were collected in a temperature-controlled Beckman XL-A. A double-sector cell, equipped with a 12 mm Epon centerpiece and quartz windows was loaded with 400-420 ml of protein sample. Data were collected at rotor speeds of 3000-60,000 rpm in continuous mode at 25 8C, with a step size of 0.005 cm and an average of three scans per point. Purified void fractions isolated by gel-filtration and stored at 4 8C were incubated at room temperature for one to two hours prior to the SVAU experiments at 25 8C. The sedimentation velocity data were analyzed as described. 30 
Scanning transmission electron microscopy (STEM)
Protofibrillar fractions of Ab were analyzed by STEM at the Brookhaven National Laboratory using 3 -10 ml of the protein samples, as described. 30 Protein samples were applied to a thin carbon film supported by a thick holey film on titanium grids, washed extensively, wicked to a thin layer, frozen rapidly to avoid formation of ice crystals, and freeze-dried overnight. The freeze-dried, unstained specimens were transferred to the STEM under vacuum and examined at 2 150 8C and 40 kV using the annular dark-field detector mode. Tobacco mosaic virus (TMV) was included in all specimens to monitor preparation quality. Digital images of 512 £ 512 pixels with 1 nm spacing were recorded at an average dose of 300-1000 enm 22 . The STEM data were analyzed as described, using the PCMass program. 64 
